文献速递前列腺癌

短期雄激素剥夺联合高剂量放疗治疗中高危局限前列腺癌:GETUG 14随机3期试验结果

Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial.
PubMed 文献 · Eur Urol · 2025-08-14

GETUG 14研究将376例局限前列腺癌患者随机分配至单纯高剂量放疗(80 Gy)或短期雄激素剥夺(4个月)联合放疗。中位随访84个月,联合组5年无病生存率显著提高(84% vs 76%,HR 0.64,95%CI 0.43-0.94),生化失败减少,但总生存无差异,两组≥2级毒性无显著差异。

要点

  • 短期ADT联合高剂量放疗可显著改善中高危局限前列腺癌的5年无病生存。
  • 联合治疗显著降低生化失败风险,但未显示总生存获益。
  • 两组急性和晚期胃肠道及泌尿生殖道≥2级毒性发生率无显著差异。

核心结论

  • 短期雄激素剥夺联合高剂量放疗耐受良好,可改善中危或高危局限前列腺癌的肿瘤学结局。

研究设计与样本

  • GETUG 14为随机3期试验,纳入376例局限前列腺癌患者,随机分配至放疗组(n=191)或短期ADT联合放疗组(n=179)。
  • 放疗剂量两组均为80 Gy;短期ADT为每月曲普瑞林联合每日氟他胺,总疗程4个月,放疗前2个月开始。
  • 主要终点为无病生存,次要终点包括总生存、生化失败、转移失败、毒性和生活质量。

主要发现

  • 在改良意向治疗人群370例中,241例(65%)为中危,107例(28%)为高危前列腺癌。
  • 存活患者中位随访84个月(四分位距62-99个月),5年无病生存率放疗组76%,联合组84%(HR 0.64,95%CI 0.43-0.94)。
  • 联合ADT降低生化失败(HR 0.45,95%CI 0.28-0.72)和转移失败(HR 0.5,95%CI 0.23-1.11),但未改善总生存(HR 1.22,95%CI 0.65-2.29)。
  • 两组≥2级急性胃肠道毒性发生率分别为26%(95%CI 20-32)和26%(95%CI 20-33),急性泌尿生殖道毒性分别为39%(95%CI 32-46%)和42%(95%CI 35-50%)。
  • 两组≥2级晚期胃肠道毒性发生率分别为21%(95%CI 16-28%)和23%(95%CI 18-30%),晚期泌尿生殖道毒性分别为30%(95%CI 24-38%)和27%(95%CI 21-34%)。

关键数值与推荐

  • 短期ADT方案为每月曲普瑞林联合每日氟他胺,总疗程4个月,放疗前2个月开始。
  • 放疗剂量两组均为80 Gy。

临床怎么用

  • 对于中危或高危局限前列腺癌患者,可考虑在80 Gy高剂量放疗基础上联合4个月短期雄激素剥夺治疗以改善无病生存。
  • 联合治疗未显示总生存获益,需结合患者风险分层和个体情况权衡治疗决策。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Few studies have compared short-term androgen deprivation (STADT) combined with high-dose radiotherapy (STADT-RT) versus high-dose radiotherapy (RT) alone in localized prostate cancer. METHODS: The GETUG 14 study randomized 376 patients to RT (n = 191) or STADT-RT (n = 179). The RT dose was 80 Gy in both arms. STADT consisted of monthly triptorelin and daily flutamide for a total duration of 4 mo, starting 2 mo before RT. Disease-free survival (DFS) was the primary endpoint. Secondary endpoints were overall survival (OS), biochemical failure (BF), metastasis failure (MF), toxicity, and quality of life. KEY FINDINGS AND LIMITATIONS: Among the 370 patients in the modified intention-to-treat population, 241 (65%) had intermediate-risk and 107 (28%) high-risk prostate cancer. At median follow-up among surviving patients of 84 mo (interquartile range 62-99 mo), the 5-yr DFS rate was 76% in RT arm versus 84% in STADT-RT arm (hazard ratio [HR] 0.64, 95% confidence interval [CI] 0.43-0.94]). ADT addition decreased BF (HR 0.45, 95% CI 0.28-0.72) and MF (HR 0.5, 95% CI 0.23-1.11) but not OS (HR 1.22, 95% CI 0.65-2.29). There were no significant differences for RT versus STADT-RT in the incidence rates for grade ≥2 toxicity in terms of acute gastrointestinal (GI) toxicity (26%, 95% CI 20-32 vs 26%, 95% CI 20-33), acute genitourinary (GU) toxicity (39%, 95% CI 32-46% vs 42%, 95% CI 35-50%), late GI toxicity (21%, 95% CI 16-28% vs 23%, 95% CI 18-30%), or late GU toxicity (30%, 95% CI 24-38% vs 27%, 95% CI 21-34%). CONCLUSIONS AND CLINICAL IMPLICATIONS: STADT is a well-tolerated and effective strategy that can enhance oncological outcomes when combined with high-dose RT, particularly for patients with intermediate- or high-risk prostate cancer.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Demogeot N, Sargos P, Salleron J, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. Eur Urol. 2025. PMID: 40816927. doi:10.1016/j.eururo.2025.07.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。